China Biologic Products Financials

China Biologic Stock Summary

China Biologic competes with BOS Better, Innovid Corp, 51Talk Online, Transportadora, and Deluxe. China Biologic Products Holdings, Inc. engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the Peoples Republic of China. China Biologic Products Holdings, Inc. is headquartered in Beijing, the Peoples Republic of China. China Biologic operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange.

China Biologic Key Financial Ratios

Generally speaking, China Biologic's financial ratios allow both analysts and investors to convert raw data from China Biologic's financial statements into concise, actionable information that can be used to evaluate the performance of China Biologic over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that China Biologic Products reports annually and quarterly.

China Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining China Biologic's current stock value. Our valuation model uses many indicators to compare China Biologic value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across China Biologic competition to find correlations between indicators driving China Biologic's intrinsic value. More Info.China Biologic Products is number one stock in return on equity category among related companies. It is number one stock in return on asset category among related companies reporting about  0.63  of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for China Biologic Products is roughly  1.59 . Comparative valuation analysis is a catch-all model that can be used if you cannot value China Biologic by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for China Biologic's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the China Biologic's earnings, one of the primary drivers of an investment's value.

Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.

If you are still planning to invest in China Biologic Products check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the China Biologic's history and understand the potential risks before investing.